Bookmark and Share

(MITD) Commences Treatment of Patients in Phase 3 FDA Clinical Trial With SERRG

Total of 660 Patients Expected to Be Treated Over a 12 Month Period

SAVANNAH, GA–(Sep 30, 2014) – MIT Holding, Inc. (OTCQB: MITD) announces the intake of patients for a FDA clinical trial. MITD through its affiliates are acting as sub-investigators for Melinta Theraputics, the primary investigator in the study managed by SERRG Savannah. MIT Holding, Inc. will generate revenues throughout this 12-month study.

Walter Drakeford, President of MIT Holding stated, “We are pleased to open this new revenue stream as a result of being selected by SERRG as a sub-investigator facility. This is evidence that our corporate re-organization and business model is capable of opening and generating new income streams through our partner affiliation programs. The facility and staff underwent intense scrutiny and was selected after a rigorous evaluation by SERRG and the State of GA. The Company is excited to continue pursuing other similar opportunities in this lucrative and specialized field.”

Patients will receive a two to four hour infusion in a blind study. The trial will last for twelve months with approximately six hundred and sixty patients treated in the entire trial at multiple facilities throughout the United States, under various sub-investigators.

For further information and news about the Company click the following links:

Click here for recent news on MITD.
Click here for study updates
Click here for current SEC filings for MITD.
Click here for ProActive Capital Group.

About MIT Holding, Inc.:
Through its affiliations, MITD distributes wholesale pharmaceuticals, licensed to administer intravenous infusions, and operates ambulatory centers where therapies are administered, and sells and rents home medical equipment. MITD has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Americas. MIT’Ds domestic wholesale pharmaceutical distribution is conducted through its contracts and affiliations, which sells pharmaceuticals to end-users and other wholesalers.

For more information, contact Mr. William Nalley, Orsay Groupe,, phone 305-515-8077 and/or visit

This news release contains “forward-looking statements” as defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements regarding beliefs, plans, expectations or intentions contain reasonable expectations, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

William Nalley
Email Contact

Tuesday, September 30th, 2014 Uncategorized